Zevra Therapeutics Inc (FRA:1GDA)
€ 4.14 -0.08 (-1.9%) Market Cap: 173.41 Mil Enterprise Value: 165.56 Mil PE Ratio: 0 PB Ratio: 3.90 GF Score: 50/100

Q3 2022 KemPharm Inc Earnings Call Transcript

Nov 09, 2022 / 10:00PM GMT
Release Date Price: €5.5 (-0.18%)
Operator

Good afternoon, and welcome to the KemPharm Third Quarter 2022 Corporate and Financial Results Conference Call. (Operator Instructions) Please be advised that todayâs call is being recorded.

I will now turn the call over to Nichol Ochsner, KemPharmâs Vice President, Investor Relations and Corporate Communications. Thank you. Maâam, you may begin.

Nichol L. Ochsner
KemPharm, Inc. - VP of IR & Corporate Communications

Good afternoon and thank you for joining our call to discuss KemPharmâs third quarter 2022 financial and corporate results.

Before we begin, I would like to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties and are subject to changes at any time, including but not limited to, statements about KemPharmâs expectations regarding future operating results. Forward-looking statements are made pursuant to the Safe harbor provisions of the federal securities laws and represent managementâs current expectations.

Actual results may differ

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot